Medical Devices: 100% (2025)

TOP 3 Markets:

1. USA: approximately 55%
2. Europe: approximately 25%
3. Asia-Pacific: approximately 15%

Teleflex Incorporated is a company specializing in the manufacturing and distribution of medical devices. The majority of revenues come from the sale of products for anesthesia, vascular access, surgery, and urology.

The largest market for Teleflex is the USA, accounting for over half of the revenue. Europe follows as the second largest market with a share of about a quarter. The Asia-Pacific region is increasingly gaining importance and contributes approximately 15% to the total revenue. This distribution reflects the global presence and strategic focus of the company, especially in developed markets.

Production Sites: USA, Mexico, Germany, Czech Republic, Malaysia, China

Teleflex Incorporated is a globally operating company that develops and produces medical technologies. The production facilities are strategically located in different countries to ensure proximity to key markets as well as efficiency in the supply chain. In the USA and Mexico, some of the main production plants are located, which are important for the North American market.

In Europe, Germany and the Czech Republic are important sites serving the European market. Malaysia and China are central production sites in Asia, covering both the Asian market and benefiting from cost advantages in these regions. This global presence enables Teleflex to flexibly respond to market demands while optimizing production costs.

Revenue Growth: 8.5% (estimated 2024)
R&D Investments: 7.2% of revenue (2024)

Teleflex Incorporated pursues a growth strategy that heavily relies on innovation and geographical expansion. The company consistently invests in research and development to expand its product range and develop new technologies in the field of medical technology. This is reflected in the R&D investments, which constitute a significant portion of the revenue.

Additionally, Teleflex aims to strengthen its market presence in emerging markets. Through strategic partnerships and acquisitions, the company plans to increase its global reach and benefit from the growing demand for medical devices in these regions.

Another focus is on improving operational efficiency to increase margins and enhance profitability. This is achieved through process optimizations and cost reduction measures.

Main raw materials: Plastics, metals, silicones
Main supplying countries: China, Germany, Mexico

Teleflex Incorporated, a company in the field of medical technology, imports various raw materials necessary for the production of their products. These include primarily plastics, metals, and silicones used in the manufacturing of medical devices and accessories.

China is one of the main suppliers of plastics and metals needed in production. Germany provides specialized medical materials and technologies, while Mexico plays an important role in the supply of raw materials due to its geographical proximity and trade agreements.

These global supply chains enable Teleflex to produce high-quality products while optimizing costs through strategic sourcing.

Market Share: Estimated at 12% in the global market for medical devices (2025).

Research & Development: Investments of approximately 6% of revenue in R&D (2024).

Patent Portfolio: Over 1,400 active patents (2025).

Teleflex Incorporated has a significant competitive advantage in the field of medical devices. The company benefits from a diversified product portfolio and a strong market presence, especially in the areas of anesthesia, cardiovascular, and urology.

Continuous investments in research and development enable Teleflex to develop and bring innovative products to the market. This strengthens its market position and increases barriers to entry for new competitors.

In addition, the extensive patent portfolio secures a technological edge for the company and protects it from imitators. The strong brand awareness and established distribution networks also contribute to solidifying the competitive advantage.

Institutional Investor Share: 90% (estimated for 2025)

Insider Buys/Sells: No significant transactions in the last year (estimated for 2025)

The institutional investor share at Teleflex Incorporated is traditionally high, indicating the trust of large investment funds and institutional investors in the company's stability and growth potential.

In 2025, no significant insider transactions are known, suggesting that the management and other insiders are either satisfied with the current valuation or do not expect any significant changes in the company's strategy.

Market share of Teleflex Incorporated: Estimated around 8% (2025)

Main competitors and their market shares:

1. Medtronic plc: around 15%
2. Boston Scientific Corporation: around 12%
3. Becton, Dickinson and Company (BD): around 10%
4. Stryker Corporation: around 9%
5. Teleflex Incorporated: around 8%
6. Abbott Laboratories: around 7%
7. Zimmer Biomet Holdings, Inc.: around 6%
8. Edwards Lifesciences Corporation: around 5%

Teleflex Incorporated is a significant player in the field of medical devices, particularly in the anesthesia and cardiovascular products segments. Teleflex's economic moat is based on its strong product pipeline, global presence, and ability to offer specialized medical solutions.

Compared to its competitors, Teleflex has a moderate economic moat. Companies like Medtronic and Boston Scientific have broader product portfolios and larger research and development budgets, giving them a stronger competitive advantage. These companies also have a larger market presence and established customer relationships that reinforce their economic moat.

However, Teleflex can stand out through its innovation and niche products that lead in specific medical applications. To expand its economic moat, Teleflex could invest in strategic partnerships and acquisitions to strengthen its market position and integrate new technologies.

Revenue Growth: 7.8% (2024) Profit Growth: 6.5% (2024) Research & Development (R&D) Expenses: 5.2% of Revenue (2024)

Teleflex Incorporated recorded a revenue growth of 7.8% in 2024, indicating solid demand for its medical products and solutions. The profit growth of 6.5% shows that the company is able to increase its profitability despite rising costs.

Another positive aspect is the investment in research and development, which accounts for 5.2% of revenue. This suggests that Teleflex is committed to expanding its product range and driving innovation, which could support long-term growth.

In summary, Teleflex Incorporated could be an attractive investment opportunity due to its stable growth and investments in innovations. However, potential investors should also consider general market conditions and specific company risks.

Dividend Yield: 0.9% (2023)
Dividend History: Continuous payout for over 10 years

Teleflex Incorporated pays a dividend, with the dividend yield standing at approximately 0.9% in 2023. The company has a long history of dividend payments and is known for its reliability in distribution.

Teleflex has maintained its dividend policy in the past, indicating a stable financial position and a solid business model. The continuous payout for over a decade speaks to the reliability of the dividend payments. Analysts view Teleflex's dividend policy as sustainable as long as the company maintains its financial performance.